Deepak Kilari, MD

Panelists discuss first-line treatment strategies for metastatic non–clear cell renal cell carcinoma, highlighting the shift from broad, subtype-agnostic approaches to histology-specific and biomarker-driven therapies, including evolving combinations of TKIs and immunotherapy tailored to tumor biology.

Panelists discuss first-line therapy for non–clear cell renal cell carcinoma, emphasizing its diverse histologies, the challenges posed by limited clinical trial data, and the importance of molecular diagnostics and multidisciplinary strategies to guide personalized treatment.